NewsSource: EClinCloud

The Earlier You Know, the More You Can Do: How Is Alzheimer's Disease Assessed?

7 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.


Every September is World Alzheimer's Month, and September 21 is World Alzheimer's Day. This year's World Alzheimer's Month theme is "The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters."


From identifying the disease earlier to more accurately assessing disease changes, clinical assessment has always been an important component of Alzheimer's disease (AD) research.


Article image

What do AD clinical studies actually assess? Many people first think of "cognitive function," such as memory, language, or executive function. In reality, a comprehensive AD study looks at far more than this[1][2][3]:

1. Has cognitive ability changed?
2. How severe is the disease?
3. Can the patient carry out daily activities independently?
4. Has quality of life been affected?
5. How much burden does the caregiver bear?
6. Are behavioral and psychological symptoms such as agitation present?
7. What changes have occurred on imaging?

These different dimensions need to be observed by combining different clinical outcome assessment (COA) tools and imaging assessment methods.


01
Overview of Scales in AD Clinical Research

COA measurements are typically performed using validated scales. EClinCloud has extensive experience with scales in the AD field. We present them by category:

1. Cognitive Function Assessment

ScaleFull NamePurpose

ADAS-Cog

Alzheimer's Disease Assessment Scale, Cognitive Subscale

Assesses patients' cognitive function and changes over time

SIB

Severe Impairment Battery

Cognitive assessment in moderate-to-severe and severe AD

MMSE

Mini-Mental State Examination

Used for early screening and cognitive assessment

MoCA

Montreal Cognitive Assessment

Screening for mild cognitive impairment and multidimensional cognitive assessment

2. Global Severity and Change

ScaleFull NamePurpose

CDR

Clinical Dementia Rating

Staging of clinical dementia severity

iADRS

Integrated Alzheimer's Disease Rating Scale

Comprehensively assesses patients' cognitive and functional status

ADCOMs

Alzheimer's Disease Composite Score

Assesses cognitive and functional changes to reflect disease progression

ADCS-CGIC

Alzheimer's Disease Cooperative Study–Clinical Global Impression of Change

Assesses patients' global clinical change and treatment response

3. Activities of Daily Living

ScaleFull NamePurpose

ADCS-ADL

Alzheimer's Disease Cooperative Study – Activities of Daily Living

Assesses activities of daily living

ADCS-ADL-MCI

ADCS-ADL (MCI version)

Assesses activities of daily living in patients with mild cognitive impairment (MCI)

FAQ

Functional Activities Questionnaire

Assesses instrumental activities of daily living

DS

Dependence Scale

Assesses dependence and care needs in patients with AD

4. Quality of Life and Caregiver Burden

ScaleFull NamePurpose

QOL-AD

Quality of Life in Alzheimer's Disease

Psychometric data on patient-perceived quality of life rated by patients and caregivers

ZBI

Zarit Burden Interview

Caregiver burden assessment

RUD-Lite

Resource Utilization in Dementia – Lite Version

Healthcare resource utilization assessment

5. Behavioral and Psychological Symptoms

ScaleFull NamePurpose

CMAI

Cohen-Mansfield Agitation Inventory

Assesses the frequency of agitated behaviors in patients with cognitive impairment

6. Imaging and Clinical Observation

ScaleFull NamePurpose

MTA

Medial temporal lobe atrophy

Assesses the degree of brain atrophy shown on MRI


02
Why Do AD Clinical Studies Need eCOA?

eCOA is not merely the digitization of paper scales. Because Alzheimer's disease progresses in a complex and long-term manner, clinical studies in this condition present distinct characteristics in efficacy evaluation, clinical endpoint design, and data capture.

Multiple Assessment Dimensions: Electronic Capture Offers Advantages

AD studies involve numerous scales and complex evaluation dimensions, creating a greater need for digital data capture and management.

Long Follow-Up Periods and High Requirements for Data Integrity

The efficacy of AD drugs or interventions requires extended follow-up to be adequately evaluated, placing high demands on data integrity.

High Assessment Subjectivity Requires Standardization to Reduce Bias

The core symptom of AD is the progressive loss of cognitive function, making measurement somewhat subjective; scoring standards may also vary across different raters (patients, caregivers, and clinicians)[4].

The Value of eCOA

Through digital workflows, eCOA provides unified management of scales, assessment roles, assessment procedures, and endpoint data. It offers clear advantages in data-collection efficiency, real-time availability, flexibility, compliance, and patient privacy protection, helping generate more reliable clinical evidence.


Article image

Data from the BN29552 (CREAD) study, a multinational clinical trial in patients with prodromal to mild AD, showed that using eCOA tools such as eADAS-Cog and eMMSE was significantly more effective in reducing scoring errors compared with paper scales[5].


03
Why Do AD Clinical Studies Need IRC?

In addition to scale-based assessments, AD clinical studies involve multiple imaging modalities such as MRI and PET to observe brain structure and disease-related imaging changes. Ensuring consistent evaluation standards across different study sites is critical for study quality control.

Subjective Variability in Image Reading Results

Different physicians may not reach completely consistent interpretations on the same MRI scan, and visual reading of PET scans also depends heavily on reader experience.

Need to maintain longitudinal consistency

AD-related imaging changes can be subtle, requiring consistent and comparable assessment of baseline and follow-up images.

Substantial challenges in multicenter studies

When images come from multiple sites, multiple scanners, and different sequence parameters, higher demands are placed on the standardization, consistency, and quality control of imaging assessment.

The value of IRC

Through centralized image management and standardized reading workflows, an IRC uses qualified and trained specialist readers to independently read and review study images against prespecified assessment criteria, reducing the impact of inter-site and individual reader variability on assessment outcomes and helping studies obtain more standardized, consistent, independent, and traceable imaging endpoint data.


Article image

The case above is from an Alzheimer's disease drug clinical study that used PET imaging to quantitatively analyze brain amyloid burden; through standardized imaging assessment, it provided objective imaging evidence for evaluating drug efficacy[6].


04
EClinCloud: Continuing deep focus on CNS clinical research

Deep CNS experience

●eCOA & IRC clinical research project experience: covering Phase I to Phase IV, from single-center to multicenter studies;
●In-depth collaboration with 10+ leading sites: including Beijing Tiantan Hospital, Shanghai Mental Health Center, Xuanwu Hospital (Capital Medical University), Huashan Hospital (Fudan University), Beijing Anding Hospital, and other sites;
●Experience across: Alzheimer's disease, depression, schizophrenia, and others.

Extensive successful case experience

Through long-term project practice, EClinCloud has continuously accumulated clinical outcome assessment (COA) experience across different development stages and study settings.

Article image

What we can do

Scale copyright management


Experienced with scales across multiple indications and supported by an extensive scale library, offering integrated services covering scale due diligence, copyright acquisition, translation and linguistic validation, and scale delivery.

eCOA data capture


A multilingual, globally compatible system that is concise and efficient, provides comprehensive functional support without adding reporting burden, and features a complete, robust closed-loop data workflow.

Rater training


One-stop management covering trainer coordination, training material preparation, rater training delivery, and training assessment, reducing inter-rater variability and improving endpoint reliability.


One-stop IRC solution


Supports reading system and independent reading service solutions across multiple therapeutic areas, helping improve the consistency and reliability of endpoint assessment.

References:

1. EMA. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease – Revision 2.
2. Molinuevo JL, et al. Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus. Alzheimer's & Dementia, 2023.
3. FDA. Early Alzheimer’s Disease: Developing Drugs for Treatment – Guidance for Industry.
4. U.S. FDA. Patient-Focused Drug Development Glossary / Clinical Outcome Assessment (COA) definitions.
5. H. Todd Feaster PsyD, Todd M. Solomon PhD, et al. The Impact of Electronic Clinical Outcome Assessments (eCOA) on Alzheimer’s Disease Clinical Trial Data Quality. Presented at the AAIC Annual Meeting, July 14–20, 2017, London, England.
6. van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.








About EClinCloud


EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies to provide global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, along with scale management, linguistic validation, rater training, and data quality analysis services to create efficient and accurate digital solutions. Backed by AI predictive models and an intelligent data platform, it dynamically assesses and helps improve drug clinical trial success rates, helping shorten drug/device R&D cycles to benefit patients.







Article image






















Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.